Please Wait
Applying Filters...
menu
    • menu
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    Ibandronate Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 915Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    28/10/2024 Polpharma
    Poland
    		 PHARMACEUTICAL WORKS POLPHARMA S.A. Starogard Gdanski PL R0-CEP 2022-073 - Rev 00 Ibandronate sodium monohydrate 2023-02-20 Valid Chemical 2771
    28/10/2024 Polpharma
    Poland
    		 PHARMACEUTICAL WORKS POLPHARMA S.A. Starogard Gdanski PL R0-CEP 2023-077 - Rev 00 Ibandronate sodium monohydrate, Type I 2023-06-30 Valid Chemical 2771